Published in Pharma Investments, Ventures and Law Weekly, June 12th, 2005
"Abbott's performance was outstanding in 2004," said White. "Overall sales increased 14%, and both of our operating groups delivered double-digit growth. Our medical products business had its best performance in a decade. And our U.S. pharmaceutical business was the second-fastest growing among our peers for the second...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly